{{distinguish|5F-AB-PINACA}}
{{Drugbox
| IUPAC_name = ''N''-(adamantan-1-yl)-1-(5-fluoropentyl)-1''H''-indazole-3-carboxamide
| image = 5F-APINACA.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = Schedule I
| legal_DE = Anlage II
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 1400742-13-3
| ATC_prefix =  
| ATC_suffix =  
| PubChem = 71711119
| ChemSpiderID = 29339965
| smiles = O=C(NC1(C[C@@H]2C3)C[C@H](C2)C[C@H]3C1)C4=NN(CCCCCF)C5=CC=CC=C54
| StdInChI = 1S/C23H30FN3O/c24-8-4-1-5-9-27-20-7-3-2-6-19(20)21(26-27)22(28)25-23-13-16-10-17(14-23)12-18(11-16)15-23/h2-3,6-7,16-18H,1,4-5,8-15H2,(H,25,28)/t16-,17+,18-,23?
| StdInChIKey = UCMFSGVIEPXYIV-XHICYHHKSA-N

<!--Chemical data-->
| C=23 | H=30 | F=1 | N=3 | O=1
| molecular_weight = 383.5 g/mol
}}

'''5F-APINACA''' (also known as '''5F-AKB48''') is an [[indazole]]-based [[synthetic cannabinoid]] that has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.caymanchem.com/app/template/Product.vm/catalog/12065 | title=AKB48 ''N''-(5-fluoropentyl) analog | publisher=Cayman Chemical | accessdate=6 July 2015}}</ref><ref>{{cite web | url=http://www.swgdrug.org/Monographs/5F-AKB48.pdf | title=5F-AKB48 | publisher=Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG) | date=18 February 2013 | accessdate=6 July 2015}}</ref> Structurally it closely resembles cannabinoid compounds from patent WO 2003/035005 but with a 5-fluoropentyl chain on the indazole 1-position, and 5F-APINACA falls within the claims of this patent, as despite not being disclosed as an example, it is very similar to the corresponding pentanenitrile and 4-chlorobutyl compounds which are claimed as examples 3 and 4.<ref>[http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2003035005 WO 2003/035005]</ref>

5F-APINACA was first identified in South Korea.<ref>{{cite journal | url=https://link.springer.com/article/10.1007/s11419-013-0213-6 | title=Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013 | author=Heesun Chung | author2=Hyeyoung Choi | author3=Sewoong Heo | author4=Eunmi Kim | author5=Jaesin Lee | journal=Forensic Toxicology |date=January 2014  | volume=32 | issue=1 | pages=82–88 | doi=10.1007/s11419-013-0213-6}}</ref> It is expected to be a potent [[agonist]] of the [[CB1 receptor|CB<sub>1</sub> receptor]] and [[CB2 receptor|CB<sub>2</sub> receptor]].<ref>{{cite web | url=http://deadiversion.usdoj.gov/drug_chem_info/spice/akb48.pdf | title=AKB48 (APINACA) and 5F-AKB48 (5F-APINACA) | publisher=Drug Enforcement Administration | date=May 2013 | accessdate=6 July 2015}}</ref> Its metabolism has been described in literature.<ref>{{cite journal | url=https://link.springer.com/article/10.1007/s11419-015-0265-x | title=Simultaneous quantification of 37 synthetic cannabinoid metabolites in human urine by liquid chromatography-tandem mass spectrometry | author=Moonhee Jang | author2=Ilchung Shin | author3=Jihyun Kim| author4=Wonkyung Yang | journal=Forensic Toxicology |date=February 2015  | doi=10.1007/s11419-015-0265-x | volume=33 | pages=221–234}}</ref><ref>{{cite journal | url=http://www.fsijournal.org/article/S0379-0738%2814%2900477-0/abstract | title=Concentrations of APINACA, 5F-APINACA, UR-144 and its degradant product in blood samples from six impaired drivers compared to previous reported concentrations of other synthetic cannabinoids | author=Ritva Karinen | author2=Silja Skogstad Tuv | author3=Elisabeth Leere Øiestad| author4=Vigdis Vindenes | journal=Forensic Science International |date=January 2015  | volume=246 | pages=98–103 | doi=10.1016/j.forsciint.2014.11.012 | pmid=25485949}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1663/abstract | title=Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry | author=Niels Bjerre Holm | author2=Anders Just Pedersen | author3=Petur Weihe Dalsgaard| author4=Kristian Linnet | journal=Drug Testing and Analysis |date=March 2015  | volume=7 | issue=3 | pages=199–206 | doi=10.1002/dta.1663 | pmid=24802286}}</ref><ref>{{cite journal | url=https://link.springer.com/article/10.1208/s12248-015-9721-0 | title=Pentylindole/Pentylindazole Synthetic Cannabinoids and Their 5-Fluoro Analogs Produce Different Primary Metabolites: Metabolite Profiling for AB-PINACA and 5F-AB-PINACA | author=Ariane Wohlfarth | author2=Marisol S. Castaneto | author3=Mingshe Zhu| author4=Shaokun Pang | author5=Karl B. Scheidweiler| author6=Robert Kronstrand | author7=Marilyn A. Huestis | journal=The AAPS Journal |date=May 2015  | volume=17 | issue=3 | pages=660–677 | doi=10.1208/s12248-015-9721-0 | pmid=25721194 | pmc=4406957}}</ref>

==Pharmacology==
5F-AKB-48 acts as a [[full agonist]] with a [[Affinity (pharmacology)#Protein-ligand binding|binding affinity]] of 1.94&nbsp;nM at [[Cannabinoid receptor type 1|CB<sub>1</sub>]] and 0.266&nbsp;nM at [[Cannabinoid receptor type 2|CB<sub>2</sub>]] [[cannabinoid]] receptors.<ref>{{cite journal|first1=Cornelius|last1=Hess|first2=ClaraT.|last2=Schoeder|first3=Thanigaimalai|last3=Pillaiyar|first4=Burkhard|last4=Madea|title=Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice|journal=Forensic Toxicology|date=1 July 2016|issn=1860-8965|pages=329–343|volume=34|issue=2|doi=10.1007/s11419-016-0320-2|first5=ChristaE.|last5=Müller|pmid=27429655|pmc=4929166}}</ref>

==Legality==

In the United States, 5F-APINACA is a [[Controlled_Substances_Act#Schedule_I_controlled_substances|Schedule I controlled substance]].<ref>{{cite web | url = https://www.deadiversion.usdoj.gov/fed_regs/rules/2016/fr1221.htm | title = Schedules of Controlled Substances: Temporary Placement of Six Synthetic Cannabinoids (5F-ADB, 5F-AMB, 5F-APINACA, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA) Into Schedule I | publisher = [[Drug Enforcement Administration]]}}</ref>

5F-APINACA is an [[Drugs controlled by the German Betäubungsmittelgesetz|Anlage II]] controlled drug in Germany since July 2013.

As of October 2015 5F-APINACA is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

5F-APINACA is banned in the Czech Republic.<ref>{{cite web | url=http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | title=Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení  vlády č. 463/2013 Sb.) | publisher=Ministerstvo zdravotnictví | language=Czech}}</ref>

==See also==
{{div col|colwidth=30em}}
* [[5F-ADB]]
* [[5F-AMB]]
* [[AB-FUBINACA]]
* [[AB-CHFUPYCA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[FUB-APINACA]]
* [[MDMB-CHMICA]]
* [[PX-3]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Adamantanes]]
[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Indazoles]]
[[Category:Fluoroalkanes]]
[[Category:Indazolecarboxamides]]